Major depressive disorder (MDD) is severely prevalent, and conventional monoaminergic
antidepressants gradually exhibit low therapeutic efficiency, especially for patients with …

Increasing evidence indicates that dysfunction of glutamate receptors is involved in the
pathophysiology of major depressive disorder (MDD). Although accumulating efforts have …

Background: A growing body of evidence suggests that glutamatergic system, especially the
abnormalities of glutamate and N-methyl-D-aspartate (NMDA) receptors contribute to the …

There have been no recent advances in drug development for mood disorders in terms of
identifying drug targets that are mechanistically distinct from existing ones. As a result …

Accumulating evidence suggests that the glutamatergic system plays important roles in the
pathophysiology and treatment of major depressive disorder (MDD). Abnormalities in the …

Major depressive disorder (MDD) is severely disabling, and current treatments have limited
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …

The discovery of robust antidepressant effects of ketamine in refractory patients has led to
increasing focus on agents targeting glutamatergic signaling as potential novel …

Depression is one of the most prevalent psychiatric disor-ders and has been estimated to
affect about 121 million people worldwide. According to the World Health Organization, it is …

Major depressive disorder (MDD) is a severe, debilitating medical illness that affects millions
of individuals worldwide. The young age of onset and chronicity of the disorder has a …

Depression is a common psychiatric condition characterized by affective, cognitive,
psychomotor, and neurovegetative symptoms that interfere with a person's ability to work …